Rounder Inc., Acquires Rights to its First Medical Product Formulation

Rounder Inc., Acquires Rights to its First Medical Product Formulation

WASHINGTON--(BUSINESS WIRE)-- Rounder Inc., (Pink OTC Market: RNDR) medical division has acquired the formulation rights for a heart healthy nutraceutical product. Roughly one-third of adults use nutraceuticals and 15 million Americans use them together with conventional medicines. A study from the Mayo clinic found that 61% of those 18 years of age and older had used a nutraceutical over the past year. With sales of nutraceutical products increasing 25% per year in the United States, the US market for nutraceuticals is expected to reach $891 million in consumer purchases by 2013. Our capture of just a small percentage of market share in this rapidly growing industry segment should result in substantial revenue for the company.

Marketing and manufacturing for the newly acquired product is expected in the first quarter of 2013 following the completion of the branding process. Distribution is then expected to begin before the end of March 2013. While the company negotiates the purchase of additional products, we are actively developing strategic partners with marketing firms that have a proven record of success relating to the development of retail accounts and product distributers within the nutraceuticals market.

Our first product to enter into our Medical Products division is classified as an anti-inflammatory, as the product assists in reducing body inflammation. Chronic inflammation can have serious effects on the human body. Science has made links between chronic inflammation and various degenerative diseases including cancer, heart disease, diabetes, Alzheimer’s and many others. When inflammation occurs, chemicals such as inflammatory cytokines are released into the blood or tissues. Inflammatory cytokines are destructive to our normal cells.

As mentioned the company is actively seeking additional nutraceutical products to build a dynamic product line. The products we seek will assist in reducing coronary artery blockage, reduce all types of body fat and lipid compounds, and generally increase the health of the human cardiovascular system.

In other events, the company has received approval from FINRA for our name change, “Fortitude Group Inc.” We still await our new trading symbol. The company remains confident that our discussions involving the acquisition of a medical device company will conclude successfully, and we will provide further updates as they become relevant.

Safe Harbor This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly revise any forward-looking statements.



Rounder Inc.
Kent Thomas, (631) 824-7661
Investor Relations
Ir-rndr@sterlingcapitol.net

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2157450, ~/Articles/ArticleHandler.aspx, 11/26/2014 2:01:49 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...